Two hundred seventy-seven patients with chronic Lyme disease were treated with tetracycline for 1 to 11 months (mean, 4 months); the outcomes for these patients were generally good. Overall, 20% of the patients were cured; 70% of the patients' conditions improved, and treatment failed for 10% of the patients. Improvement frequently did not take place for several weeks; after 2 months of treatment, 33% of the patients' conditions were significantly improved (degree of improvement, 75% -100%), and after 3 months of treatment, 61% of the patients' conditions were significantly improved. Treatment outcomes for seronegative patients (20% of all patients) were similar to those for seropositive patients. Western immunoblotting showed reactions to one or more Borrelia burgdorferi -specific proteins for 65% of the patients for whom enzyme-linked immunosorbent assays were negative. Whereas age, sex, and prior erythema migrans were not correlated with better or worse treatment outcomes, a history of longer duration of symptoms or antibiotic treatment was associated with longer treatment times to achieve improvement and cure. These results support the use of longer courses of treatment in the management of patients with chronic Lyme disease. Controlled trials need to be conducted to validate these observations.
The clinical spectrum of illness caused by Borrelia burgdorfpositive experience with tetracycline therapy for patients with symptoms compatible with those of chronic Lyme disease [15] , eri has been known since the early 1900s, even though the causative organism was not identified until 1982 [1 -3] . In many subsequent patients were treated with this antibiotic. The results of tetracycline treatment for 277 patients seen between Europe, the disease was described in primarily neurological terms [4] , whereas in the United States (where the disease was 1988 and 1995 are reported here. first described as a cluster of cases of arthritis occurring in young children in Old Lyme, CT), the emphasis initially was
Patients and Methods placed on the joint manifestations [5] . Indeed, the case definition of the Centers for Disease Control and Prevention (CDC) Patients were seen at the University of Connecticut's Lyme includes arthritis but not arthralgias and other neurological Disease Clinic (Farmington, CT) between 1988 and 1993 and symptoms [6] . It has since become recognized that chronic at Boston University Medical Center (Boston) from 1993 to symptoms consisting of fatigue plus musculoskeletal pains, 1995. The patients described herein are those whose symptoms paresthesias, and other neuropsychiatric dysfunctions are typiexisted for ú3 months with or without a history of tick bite cal symptoms of chronic Lyme disease [7 -9] .
(29% with known bite) or rash (44% with known rash). Inclusion Laboratory support for the diagnosis of Lyme disease beyond criteria were a combination of at least two of three sets of major the erythema migrans phase has suffered from a lack of sensisymptoms: fatigue, neurological complaints (e.g., paresthesias, tive and definitive tests: ELISAs have been unreliable cognitive dysfunction, and radicular pains), and musculoskeletal [10, 11] ; western immunoblotting has been more sensitive but complaints (e.g., arthralgias, myalgias, and weakness). Many more difficult to perform and standardize; and PCR analysis patients had other symptoms such as visual and auditory disturof DNA is insufficiently sensitive [12] . Furthermore, none of bances, palpitations, and gastrointestinal and genitourinary dysthe laboratory tests can be used to estimate the extent of infecfunction (the combination of major symptoms and other symption, its prior duration, or its prognosis.
toms has also been noted in other studies [7] [8] [9] 14] ). The treatment of chronic Lyme disease is also inadequately All patients were evaluated for alternative diagnoses such as defined. Although recommendations have been made for 1 rheumatoid arthritis, systemic lupus erythematosus, and other month of treatment [13] , there have been no trials to test or neurological disorders. Fibromyalgia and/or chronic fatigue support this view. Most physicians practicing in this area behad been diagnosed for some patients; if these patients met the lieve that a longer duration of treatment is needed to effect clinical inclusion criteria, they were offered a trial of tetracysignificant improvement or cure [14] . Because of our initial cline therapy. patient's condition improved. For those patients whose symptoms completely resolved, treatment was generally continued for one more month. For those patients whose conditions improved but whose symptoms did not resolve, treatment was A comparison of treatment outcomes according to seroposigenerally continued for one to two more months before stoptivity or seronegativity is shown in table 2. There were no ping or changing therapy. For those patients for whom treatsignificant differences in treatment outcomes between those ment failed, therapy was continued for at least 3 months before patients for whom western immunoblotting or EIA was positive being judged a failure.
and those patients who were seronegative. A treatment cure was defined as the absence of symptoms Age, sex, and treatment outcome. The age of patients for 1 year or more following cessation of therapy; significant treated with tetracycline ranged from 13 to 75 years (mean, improvement was defined as having recovered §75% of previ-39 years). There were no differences in treatment outcomes ous normal function, as assessed by the patient. The conditions according to age (data not shown). Two-thirds of the patients of patients whose symptoms resolved completely by the end were female; there was a tendency to fewer cures (14% vs. of treatment but who subsequently had relapsing symptoms 32%, respectively) and more failures (11% vs. 7%, respecafter tetracycline therapy was discontinued were considered tively) for females than for males (table 3) . significantly improved but not cured; these patients usually Duration of prior symptoms and treatment outcome. Parelapsed within 2 -6 weeks following therapy.
tients whose symptoms had been present for ú1 year had fewer cures and more treatment failures than did those patients whose symptoms had been present for õ1 year (table 4) . Patients with symptoms for ú3 years fared poorer than did those with Results symptoms for either 1 -3 years or õ1 year. The duration of Serological reactivity and treatment outcome. A total of prior symptoms was also directly correlated with the time to 277 patients were treated with tetracycline for 1 month or more. onset of any improvement (i.e., the longer the duration of prior A comparison of the results of EIA and western immunoblotsymptoms, the longer the time until any signs of improvement ting for these patients is shown in table 1. Overall, EIA or were noted; table 5). The mean time to onset of any improvewestern immunoblotting was positive for 81% of the patients. ment was 0.9 month. EIA was positive for 29% of the patients, and western immuThe extent of improvement at 2 and 3 months after the noblotting was positive for 81% of the patients. Whereas EIA initiation of tetracycline therapy is shown in figure 1. By 2 was positive for 0.8% of the patients for whom western immumonths of therapy, the mean degree of improvement was 50% -noblotting was negative, EIA was negative for 52% of the 75%, with only one-third of the patients believing that their patients for whom western immunoblotting was positive.
conditions had significantly improved (degree of improvement, 75% -100%); by 3 months, 61% of the patients believed that their conditions had improved §75%. Duration of treatment and treatment outcome. Patients were treated for as little as 1 month or as long as 11 months (median, 4 months). Most patients were treated for between 3 and 6 months. The duration of treatment was correlated with the duration of prior symptoms (data not shown). tetracycline therapy had fewer cures (16% vs. 31%, respec-Å 0 -25%; Å 25% -50%; Å 50% -75%; and Ω Å 75% -100%. tively) and a generally poorer outcome than did those who were not previously treated (table 6). These poorer outcomes were not dependent on the duration of prior symptoms. Discussion Treatment outcome and serological reactivity. The results of western immunoblotting for the first 86 patients studied
The optimum criteria and methods for the diagnosis and before and after treatment are shown in table 7. Western immutreatment of chronic Lyme disease remain to be defined. Most noblotting was positive for IgM for 94% of the symptomatic practitioners use a clinical definition that includes a combinapatients, and IgM was the only antibody found for 36% of tion of symptoms and signs with or without positive serological these patients. With successful treatment, the rate of IgM serosupport [14] , but there are some who advocate a diagnosis that positivity decreased to 25%, compared with a rate of 69% for requires positive serologies [16] . A recommendation was made IgG seropositivity; 22% of the patients became seronegative.
at a meeting of territorial public health officers in the fall of Retreatment and treatment outcome. Ninety-eight patients 1995 that western blotting be done only to confirm screening who were cured or whose conditions were improved at the end EIAs that reveal positive antibody titers [6] . According to our of treatment but who had relapsing symptoms were retreated results and a physician survey [14] , this approach would not with antibiotics (table 8) . Fifty of these patients were given diagnose ú50% of the cases of chronic Lyme disease. Until another course of tetracycline therapy (cure rate, 28%; signifibetter criteria are established, it would seem advisable to reccant improvement rate, 70%). Of thirty-five patients treated ommend that western immunoblotting, especially testing for with a combination of a macrolide and hydroxychloroquine, IgM, be conducted for all patients who meet the clinical criteria. 74% were cured or believed that their conditions were further IgM reactions may represent reactivation of latent disease improved. Of 13 patients treated with iv ceftriaxone, one was or persistent infection and have been noted in other chronic cured, and 10 noted significant improvement in their condiinfections (e.g., toxoplasmosis The optimum treatment for chronic Lyme disease also re-IV ceftriaxone 1 10 2 mains to be delineated. No controlled clinical trials have been conducted to date, yet there appear to be strong opinions regarding the type and duration of any antibiotic therapy [20] . In draws support from what is known about other chronic infeccontrast, there is a consensus that a 3-to 4-week course of tions, which most, if not all, have an intracellular reservoir therapy with a tetracycline or b-lactam antibiotic appears to (e.g., Chlamydia, Legionella, Leishmania, Rickettsia, and yield a successful outcome of the earliest manifestation of Mycobacterium tuberculosis infections). An intracellular locaLyme disease (erythema migrans) [13] . Although it has yet to tion could also explain the difficulties posed for b-lactam antibe established whether all or most cases of chronic Lyme disbiotics as treatment of Lyme disease; this location is supported ease are due to persistent infection, our results support the by data from a tissue culture model of B. burgdorferi infection hypothesis that it is a persistent infection and provide the basis in which ceftriaxone was ineffective against intracellular organfor a reasonable approach to its management.
isms [22] . The rationale for our use of tetracycline hydrochloride for
Our results show that a 3-to 6-month course of treatment the treatment of patients with chronic Lyme disease arose from is associated with cure or significant improvement in 80% -several observations. One observation was that patients being 90% of patients with chronic Lyme disease. The most imseen in our Lyme disease clinic who had been previously portant determinant of treatment duration and outcome appears treated with b-lactam antibiotics, including iv ceftriaxone, were to be the duration of symptoms before tetracycline therapy not routinely cured or did not believe that their conditions were (tables 4 and 5). Improvement was noted to begin as early as significantly improved, even after several months of therapy; 1 -2 weeks, but in patients with symptoms for ú1 year, the serological tests for most of these patients were unequivocally onset of any improvement frequently did not occur before positive. Another observation was that patients treated with 4 -6 weeks of therapy had been given. It would not then be doxycycline (100 mg twice daily) had some improvement in surprising if both patients and physicians would conclude that their conditions that was not sustained.
this mode of therapy was ineffective when there was no imWhen the pharmacologic properties of doxycycline and tetraprovement after 3 -4 weeks of therapy. This slow rate of imcycline hydrochloride are compared, the absorption of doxycyprovement may correlate best with organisms for which the cline is sometimes better at comparable doses, but 500 mg of rates of multiplication and metabolism are slow, as is known tetracycline three times daily achieves higher serum levels than for B. burgdorferi [23] . We speculate that the frequently noted does 100 mg of doxycycline twice daily [21] . Because doxycycycles of improvement and relapse could be consistent with cline is also highly bound to proteins (which accounts for its the varying metabolic activities of a heterogeneous population longer half-life), the amount of free drug available to diffuse of spirochetes. into tissues is less than that of tetracycline [21] .
Our results also show that tetracycline is apparently effective A third observation was the hypothesis that chronic Lyme in resolving symptoms associated with CNS function (i.e., cogdisease is a persistent intracellular infection. This hypothesis nition and emotions); these symptoms are probably secondary to encephalopathy. Recent studies with nonhuman primates have demonstrated that the CNS, especially sensory functions, is the main target of B. burgdorferi infection [24] . In this 
